Skip to content
2000
Volume 26, Issue 1
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Background

Previous studies have shown that WZC can increase tacrolimus blood concentration when co-administered. However, limited knowledge exists regarding the pharmacokinetics of both tacrolimus and the bioactive lignans in WZC when administered simultaneously in renal transplantation patients.

Aims

This study aimed to investigate the pharmacokinetics of tacrolimus and multiple bioactive lignans in capsule (WZC) when co-administered with 5 bioactive components in renal transplantation recipients.

Objectives

The objective of this study was to develop a method for simultaneous quantification of tacrolimus and multiple bioactive lignans in WZC using liquid-liquid extraction followed by LC-MS/MS analysis.

Methods

A liquid-liquid extraction method combined with LC-MS/MS analysis was developed for simultaneous quantification of tacrolimus and multiple bioactive lignans in WZC. Human whole blood samples were analyzed, and the accuracy and precision of the method were evaluated.

Results

The developed method showed good linearity and accuracy for the quantification of tacrolimus and bioactive lignans in WZC. Pharmacokinetic analysis revealed significant effects of WZC co-administration on both V/F and CL/F in renal transplantation patients.

Conclusion

This study demonstrated that simultaneous administration of WZC had notable effects on the pharmacokinetics of tacrolimus and bioactive lignans in renal transplantation patients. The developed method proved to be reliable and sensitive for determining the whole blood concentrations of tacrolimus and WZC, making it suitable for pharmacokinetic studies in transplant patients.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002320686250310054152
2025-03-19
2025-12-26

  • From This Site

    /content/journals/cdm/10.2174/0113892002320686250310054152
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ChristiansU. JacobsenW. BenetL.Z. LampenA. Mechanisms of clinically relevant drug interactions associated with tacrolimus.Clin. Pharmacokinet.2002411181385110.2165/00003088‑200241110‑0000312190331
     [Google Scholar]
  2. StaatzC.E. TettS.E. Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients.Clin. Pharmacokinet.20155410993102510.1007/s40262‑015‑0282‑226038096
     [Google Scholar]
  3. HendricksonR.J. KarrerF.M. WachsM.E. SlaterK. BakT.E. KamI. Pediatric liver transplantation.Curr. Opin. Pediatr.200416330931310.1097/01.mop.0000127160.82531.7715167019
     [Google Scholar]
  4. KellyD. JaraP. RodeckB. LykavierisP. BurdelskiM. BeckerM. GridelliB. BoillotO. ManzanaresJ. RedingR. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: Randomised European multicentre trial.Lancet200436494391054106110.1016/S0140‑6736(04)17060‑815380964
     [Google Scholar]
  5. LiL. LiC.J. Tacrolimus in preventing transplant rejection in Chinese patients – optimizing use.Drug Des. Devel. Ther.2015947348510.2147/DDDT.S4134925609922
     [Google Scholar]
  6. Schutte-NutgenK. TholkingG. SuwelackB. ReuterS. Tacrolimus - Pharmacokinetic considerations for clinicians.Curr. Drug Metab.201819434235010.2174/138920021966618010110415929298646
     [Google Scholar]
  7. ChenX. WangD.D. XuH. LiZ.P. Population pharmacokinetics and pharmacogenomics of tacrolimus in Chinese children receiving a liver transplant: Initial dose recommendation.Transl. Pediatr.20209557658610.21037/tp‑20‑8433209719
     [Google Scholar]
  8. QinX.L. BiH.C. WangX.D. LiJ.L. WangY. XueX.P. ChenX. WangC.X. XuL.J. WangY.T. HuangM. Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506).Int. J. Pharm.20103891-211412110.1016/j.ijpharm.2010.01.02520097278
     [Google Scholar]
  9. QinX.L. YuT. LiL.J. WangY. GuH.M. WangY.T. HuangM. BiH.C. Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus.Phytomedicine2013203-437537910.1016/j.phymed.2012.11.00823267661
     [Google Scholar]
  10. BowmanL.J. BrennanD.C. The role of tacrolimus in renal transplantation.Expert Opin. Pharmacother.20089463564310.1517/14656566.9.4.63518312164
     [Google Scholar]
  11. WeiH. TaoX. DiP. YangY. LiJ. QianX. FengJ. ChenW. Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats.Drug Metab. Dispos.20134171398140310.1124/dmd.112.05030223628674
     [Google Scholar]
  12. ChenZ. LiuF. ZhengN. GuoM. BaoL. ZhanY. ZhangM. ZhaoY. GuoW. DingG. Wuzhi capsule (Schisandra Sphenanthera extract) attenuates liver steatosis and inflammation during non-alcoholic fatty liver disease development.Biomed. Pharmacother.201911028529310.1016/j.biopha.2018.11.06930522014
     [Google Scholar]
  13. QuJ. BianR. LiuB. ChenJ. ZhaiJ. TengF. GuoW. WeiH. The pharmacokinetic study of tacrolimus and Wuzhi capsule in Chinese liver transplant patients.Front. Pharmacol.20221395616610.3389/fphar.2022.95616636188616
     [Google Scholar]
  14. QinX. ChenX. ZhongG. FanX. WangY. XueX. WangY. HuangM. BiH. Effect of Tacrolimus on the pharmacokinetics of bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) and the potential roles of CYP3A and P-gp.Phytomedicine201421576677210.1016/j.phymed.2013.12.00624462213
     [Google Scholar]
  15. JiangW. WangX. XuX. KongL. Effect of Schisandra sphenanthera extract on the concentration of tacrolimus in the blood of liver transplant patients.Int. J. Clin. Pharmacol. Ther.201048322422910.5414/CPP4822420197017
     [Google Scholar]
  16. QinX.L. ChenX. WangY. XueX.P. WangY. LiJ.L. WangX.D. ZhongG.P. WangC.X. YangH. HuangM. BiH.C. In vivo to in vitro effects of six bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) on the CYP3A/P-glycoprotein-mediated absorption and metabolism of tacrolimus.Drug Metab. Dispos.201442119319910.1124/dmd.113.05389224195812
     [Google Scholar]
  17. XinH.W. LiQ. WuX.C. HeY. YuA.R. XiongL. XiongY. Effects of Schisandra sphenanthera extract on the blood concentration of tacrolimus in renal transplant recipients.Eur. J. Clin. Pharmacol.201167121309131110.1007/s00228‑011‑1075‑721656210
     [Google Scholar]
  18. XinH.W. WuX.C. LiQ. YuA.R. ZhuM. ShenY. SuD. XiongL. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers.Br. J. Clin. Pharmacol.200764446947510.1111/j.1365‑2125.2007.02922.x17506780
     [Google Scholar]
  19. WeiH. MiaoH. YunY. LiJ. QianX. WuR. ChenW. Validation of an LC-MS/MS method for quantitative analysis of the 5 bioactive components of Wuzhi capsule in human plasma samples.Ther. Drug Monit.201436678178810.1097/FTD.000000000000007925392942
     [Google Scholar]
  20. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD., Guidance for Industry: Bioanalytical Method Validation, FDA.2013Available from:https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry (Accessed on: April 26, 2021).
  21. StaatzC.E. TettS.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.Clin. Pharmacokinet.2004431062365310.2165/00003088‑200443100‑0000115244495
     [Google Scholar]
  22. ZhangC. RenX. LiuY. HuangL. FengY. ZhangX. Effects of wuzhi capsule on whole-blood tacrolimus concentration levels: A systematic review and meta-analysis.Ther. Drug Monit.2024461334110.1097/FTD.000000000000115538150711
     [Google Scholar]
  23. ChengF. LiQ. WangJ. ZengF. ZhangY. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients.J. Clin. Pharm. Ther.20214661636164910.1111/jcpt.1349334342024
     [Google Scholar]
  24. HeQ. BuF. WangQ. LiM. LinJ. TangZ. MakW.Y. ZhuangX. ZhuX. LinH.S. XiangX. Examination of the Impact of CYP3A4/5 on Drug–Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A physiologically based pharmacokinetic modeling approach.Int. J. Mol. Sci.2022239448510.3390/ijms2309448535562875
     [Google Scholar]
  25. TengF. WangW. ZhangW. QuJ. LiuB. ChenJ. LiuS. LiM. ChenW. WeiH. Effect of hepar‐protecting Wuzhi capsule on pharmacokinetics and dose‐effect character of tacrolimus in healthy volunteers.Biopharm. Drug Dispos.202243411912910.1002/bdd.231235180322
     [Google Scholar]
  26. YanL. YangZ.Q. ShiY.Y. RenJ. YangC.L. WanZ.L. BaiY.J. LuoL.M. WangL.L. LiY. Effects of wuzhi capsules on blood concentration of tacrolimus in renal transplant recipients.Ann. Transplant.20192459460410.12659/AOT.91898031712547
     [Google Scholar]
  27. ZhangS.F. TangB.H. WeiA. DuY. GuanZ.W. LiY. Effect of drug combination on tacrolimus target dose in renal transplant patients with different CYP3A5 genotypes.Xenobiotica202252331232110.1080/00498254.2022.206425235395919
     [Google Scholar]
  28. HuangS. SongW. JiangS. LiY. WangM. YangN. ZhuH. Pharmacokinetic interactions between tacrolimus and Wuzhi capsule in liver transplant recipients: Genetic polymorphisms affect the drug interaction.Chem. Biol. Interact.202439111090610.1016/j.cbi.2024.11090638340974
     [Google Scholar]
  29. ZhangH. BuF. LiL. JiaoZ. MaG. CaiW. ZhuangX. LinH.S. ShinJ.G. XiangX. Prediction of Drug–Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically‐Based Pharmacokinetic Modelling.Basic Clin. Pharmacol. Toxicol.2018122333134010.1111/bcpt.1291428945011
     [Google Scholar]
  30. HeQ. BuF. ZhangH. WangQ. TangZ. YuanJ. LinH.S. XiangX. Investigation of the impact of CYP3A5 polymorphism on drug–drug interaction between tacrolimus and schisantherin a/schisandrin a based on physiologically-based pharmacokinetic modeling.Pharmaceuticals (Basel)202114319810.3390/ph1403019833673653
     [Google Scholar]
  31. SeoH.J. JiS.B. KimS.E. LeeG.M. ParkS.Y. WuZ. JangD.S. LiuK.H. Inhibitory effects of Schisandra lignans on cytochrome P450s and uridine 5′-diphospho-glucuronosyl transferases in human liver microsomes.Pharmaceutics202113337110.3390/pharmaceutics1303037133802239
     [Google Scholar]
/content/journals/cdm/10.2174/0113892002320686250310054152
Loading
Effect of Wuzhi Capsule (WZC) on the Pharmacokinetics of Tacrolimus in Renal Transplantation Recipients
Current Drug Metabolism 26, 47 (2025); https://doi.org/10.2174/0113892002320686250310054152
/content/journals/cdm/10.2174/0113892002320686250310054152
/content/journals/cdm/10.2174/0113892002320686250310054152
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): concentration; LC-MS/MS; pharmacokinetics; renal transplantation; tacrolimus; Wuzhi capsule

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test